Literature DB >> 2826035

Transfection of murine multi-potent haemopoietic stem cells with an E. coli DNA alkyltransferase gene confers resistance to the toxic effects of alkylating agents.

J Jelinek1, K Kleibl, T M Dexter, G P Margison.   

Abstract

O6-alkylguanine-DNA-alkyltransferase (ATase)-deficient murine haemopoietic stem cells were transfected, following electroporation, with a G418-selectable expression vector containing the protein coding region of the Escherichia coli ATase gene ada. Clones of cells that were resistant to G418 or the chloroethylating agent mitozolomide (Mz) were selected and most were shown to express very high levels of bacterial gene-encoded ATase. In comparison with control cells that were transfected with the parent vector, the ATase-expressing clones were considerably more resistant to the toxic effects of the methylating agents N-methyl-N-nitrosourea and methylmethanesulphonate or the chloroethylating agents Mz or taurine chloroethylnitrosourea, but unchanged in their susceptibility to the bis-chloroethylating agent nitrogen mustard. Thus alkylation damage in DNA that can be repaired by the E. coli ATase constitutes the principal lethal lesion produced by alkylating agents in murine haemopoietic stem cells and the ATase deficiency in these cells can be complemented by electroporation-mediated gene transfection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2826035     DOI: 10.1093/carcin/9.1.81

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  12 in total

Review 1.  Chemoprotection of normal tissues by transfer of drug resistance genes.

Authors:  J A Rafferty; I Hickson; N Chinnasamy; L S Lashford; G P Margison; T M Dexter; L J Fairbairn
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

2.  Differential inactivation of mammalian and Escherichia coli O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine.

Authors:  R H Elder; G P Margison; J A Rafferty
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

3.  In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.

Authors:  S M Lee; N Thatcher; D Crowther; G P Margison
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Expression of the E.coli 3-methyladenine DNA glycosylase I gene in mammalian cells reduces the toxic and mutagenic effects of methylating agents.

Authors:  A Klungland; L Fairbairn; A J Watson; G P Margison; E Seeberg
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

5.  Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

Authors:  S M Lee; N Thatcher; D Crowther; G P Margison
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

6.  Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

Authors:  S M Lee; N Thatcher; M Dougal; G P Margison
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

7.  Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.

Authors:  S M Lee; G P Margison; N Thatcher; P J O'Connor; D P Cooper
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

8.  O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines.

Authors:  M C Walker; J R Masters; G P Margison
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

9.  Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.

Authors:  J C Baer; A A Freeman; E S Newlands; A J Watson; J A Rafferty; G P Margison
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

10.  Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.

Authors:  S M Lee; G P Margison; A A Woodcock; N Thatcher
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.